PITTSBURGH, Pa. , Sept. 19, 2017 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (“Krystal”), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced the pricing of its initial public offering.